Zuberitamab for Epstein-Barr virus infection after stem cell transplant
Treatments studied
Part of Infections clinical trials.
This trial tests a drug called Zuberitamab for people who develop an Epstein-Barr virus (EBV) infection after a stem cell transplant. The drug may help control the infection and prevent related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a donor (allogeneic).
- You have an active EBV infection, shown by a blood test (EBV DNA in plasma) or by a biopsy confirming EBV-related disease.
- You are 18 years or older.
- You are not infected with HIV, hepatitis B, or hepatitis C.
- You are generally able to care for yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving rituximab early after a stem cell transplant can prevent a common viral infection (EBV) from becoming serious. It may help reduce complications and improve recovery.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.